Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
NCT ID: NCT02541110
Last Updated: 2015-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2015-09-30
2016-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
NCT02854501
Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia
NCT02350036
Homocysteine in Critically Ill Preeclampsia
NCT06413576
First Trimester Prediction of Preeclampsia and Fetal Growth Restriction
NCT02379494
Evaluation of Fetal Cardiac Function and Vascular Hemodynamics in Intrauterine Growth Restriction
NCT03108040
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Uterine artery doppler between 18th \& 22nd weeks.
Method 1: Screen positive cases will be considered if homocysteine level above 6.3umol/l
Method 2: Screen positive cases will be considered if they had bilateral notches and a mean resistivity index (RI) above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7.
Method 3: Screen positive cases will be considered if they had bilateral notches and a mean RI above 0.55, or unilateral notches and a mean RI above 0.65, or absence of notches and a mean RI above 0.7 combined with homocysteine cut off value of 6.3umol / l.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* non intact renal function
* hypertension
* diabetes
* folic acid supplements
* antifolate drugs
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
suzy abdelaziz Abdelhamid
lecturer of Obgyn
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
suzy abdelaziz, M.D.
Role: PRINCIPAL_INVESTIGATOR
kasrelaini hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Obgyn. .
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.